[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Medical University of Warsaw\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":696},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,61,0,25,[9,52,78,105,136,165,197,222,246,276,306,336,361,391,427,450,471,498,523,545,570,600,620,647,672],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100644323","the-effectiveness-of-the-self-assembling-peptide-p11-4-in-the-remineralization-of-enamel-carious-white-spot-lesions-100644323",false,"NCT07664046","The Effectiveness of the Self-Assembling Peptide P11-4 in the Remineralization of Enamel Carious White Spot Lesions","A Three-arm Randomized Controlled Trial Evaluating the Effectiveness of Self- Assembling Peptide P11-4 in the Remineralization of Enamel Carious White Spot Lesions","WSL-Curodont","Inclusion Criteria:\n\n1. Age \\>10 years and \\\u003C18 years.\n2. Presence of at least 2 active enamel carious white spot lesions on a smooth tooth surface (labial\u002Fbuccal surfaces of permanent teeth) based on International Caries Detection (ICDAS II) and Assessment System -Lesion Activity Assessment (ICDAS-LAA), and Lesion Activity Assessment (LAA criteria).\n3. Tooth eligible for treatment:\n\n   1. Vital pulp,\n   2. no loss of hard dental tissues within the investigated lesion (ICDAS II) code 1 or 2 , LAA code 1, ICDAS-LAA\\>7;\n   3. QLF score parameters consistent with demineralization without loss of tissue continuity- code 1 or 2),\n   4. no history of trauma to the tooth.\n4. Systemically healthy patient.\n5. No contraindications to the use of fluoride preparations.\n6. No fixed orthodontic appliance.\n7. Written consent for participation in the study signed by the legal guardian, or by the legal guardian and the patient.\n\nExclusion Criteria:\n\n1. Systemic diseases or chronic medication use due to chronic conditions.\n2. Viral\u002Fbacterial illness on the day of the visit, e.g., herpetic stomatitis, influenza, tonsillitis (temporary restriction).\n3. Pregnancy or breastfeeding.\n4. Allergy to any component of the SAP P11-4 preparation or the fluoride varnish.\n5. Professional fluoride prophylaxis performed \\\u003C3 months ago.\n6. Presence of cavitation (loss of hard tissues) in the treated tooth - ICDAS II code ≥3, ICDAS-LAA\\\u003C7, LAA code 0, 2-9.\n7. Carious WSL previously treated with the Icon resin infiltrant (methacrylate resin).\n8. Developmental enamel defects.\n9. Patient undergoing orthodontic treatment with fixed appliances.\n10. Inability to ensure regular follow-up visits.\n11. Lack of cooperation from the guardian or the patient.\n12. Refusal to participate in the study and\u002For absence of written consent.","ALL","10 Years","18 Years",{"count":22,"type":23},75,"ESTIMATED","INTERVENTIONAL",[26],"NA","This is three-arm Randomized Controlled Trial. The main goal is to evaluate the effectiveness of self-assembling peptide P11-4 (SAP P11-4) in the remineralization of enamel carious white spot lesions. Participants with carious white spot lesions will be assigned to one of three study groups and remineralisation agents will be applied according to the study protocol. The primary objective is to assess changes in the carious white spot lesions over time using quantitative light-induced fluorescence and clinical evaluation.",[29],"White Spot Lesions on Smooth Surface of Tooth",[31,32,33,34,35,36,37,38],"Curodont Repair","SAP P11-4","Self-Assembling Peptide P11-4","Remineralisation","Quantitative Light-Induced Fluorescence","Fluoride Varnish","Pediatric Dentistry","White Spot Lesions","RECRUITING","2026-06-16",{"date":42,"type":43},"2026-06-23","ACTUAL",{"date":45,"type":43},"2026-02-02",{"date":47,"type":23},"2027-12-14",{"name":49,"class":50},"Medical University of Warsaw","OTHER",1,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":18,"minAge":20,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100641451","remodelling-of-the-lower-airways-in-chronic-cough-100641451","NCT07659860","Remodelling of the Lower Airways in Chronic Cough","Does Chronic Cough Lead to Injury and Remodelling of the Lower Airways?","Inclusion criteria for the study group:\n\n1. age between 18 and 75 years,\n2. chronic cough of at least one year duration, with no previous treatment (at least 2 previous unsuccessful attempts at pharmacological treatment of cough)\n3. negative history of smoking (at least 6 months of abstinence),\n4. negative history of treatment with angiotensin-converting enzyme inhibitors (ACEI),\n5. normal chest radiograph or with changes not relevant to cough formation,\n6. no respiratory tract infections in the past 6 weeks,\n7. written consent from the patient to participate in the study.\n\nExclusion Criteria:\n\n1. patients less than 18 and more than 75 years of age,\n2. cough lasting less than 12 months,\n3. active smoking or abstinence period of less than 6 months,\n4. respiratory tract infection 6 weeks prior to inclusion or at the time of study conduct - retry inclusion after 6 weeks,\n5. cancer or interstitial lung disease,\n6. contraindications to functional testing, sputum induction or bronchoscopy","75 Years",{"count":61,"type":23},40,"OBSERVATIONAL","The aim of the study is to assess if chronic cough leads to injury and remodelling of the airways. We plan to analyse bronchial injury and remodelling in patients with refractory chronic cough lasting longer than 12 month . Assessment of injury mediators will be performed in blood and bronchoalveolar lavage fluid. Remodelling features will be analysed based on chest CT scan and pathologic specimens. Injury of epithelium will be assessed in bronchial biopsy specimens. The relationship between the duration, severity of chronic cough, and bronchial inflammation, damage, remodelling will be analysed.",[65],"Chronic Cough",[67,68],"remodelling","chronic cough","2026-06-15",{"date":71,"type":43},"2026-06-22",{"date":73,"type":43},"2022-10-01",{"date":75,"type":23},"2026-08-30",{"name":49,"class":50},4,{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":99,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":51},"100641699","cardiovascular-assessment-5-years-after-mis-c-100641699","NCT07659847","Cardiovascular Assessment 5 Years After MIS-C","Cardiovascular Evaluation 5 Years After Multisystem Inflammatory Syndrome in Children (MIS-C)","Inclusion Criteria:\n\n* For the MIS-C group: History of MIS-C diagnosed according to World Health Organization (WHO) criteria\n* For all participants: Written informed consent from a parent or legal guardian and, where applicable, assent\u002Fconsent from participants aged 16 years or older \u002F\n\nExclusion Criteria:\n\nMIS-C group:\n\n1. Known heart disease, including congenital heart disease.\n2. Significant chronic disease affecting growth, development, or daily functioning.\n\nControl group:\n\n1. Elimination diet.\n2. Competitive athletic training.\n3. Known heart disease, including congenital heart disease.\n4. Significant chronic disease affecting growth, development, or daily functioning.",true,{"count":87,"type":23},90,"Multisystem inflammatory syndrome in children (MIS-C) is a severe complication associated with SARS-CoV-2 infection that frequently affects the cardiovascular system. Although acute cardiac abnormalities usually resolve, the long-term cardiovascular consequences of MIS-C remain uncertain. Previous follow-up of this cohort 2 years after MIS-C identified signs of subclinical cardiovascular abnormalities compared with healthy controls.\n\nThis cross-sectional study aims to evaluate cardiovascular health in individuals 5 years after MIS-C. Participants with a history of MIS-C will be compared with age- and sex-matched healthy controls using cardiovascular imaging, vascular assessments, cardiopulmonary exercise testing, and biomarkers of endothelial injury.",[90,91],"Multisystem Inflammatory Syndrome in Children (MIS-C)","SARS-CoV-2 Infection",[93,94,95,96,97,90,98],"Pediatric Inflammatory Multisystem Syndrome (PIMS)","SARS-CoV-2","Endothelial Dysfunction","Cardiovascular Health","Long-Term Outcomes","Arterial Stiffness",{"date":71,"type":43},{"date":101,"type":43},"2025-11-22",{"date":103,"type":23},"2027-03-31",{"name":49,"class":50},{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":85,"sex":18,"minAge":20,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":24,"phases":115,"briefSummary":116,"conditions":117,"keywords":122,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":51},"100639898","mental-rehearsal-in-emergency-cricothyroidotomy-training-100639898","NCT07625072","Mental Rehearsal in Emergency Cricothyroidotomy Training","Effect of Mental Rehearsal Training on the Effectiveness of Emergency Cricothyroidotomy Training Among Medical Personnel.","MERIT","Inclusion Criteria:\n\n* Medical personnel, including anesthesiology and intensive care specialists, residents, and nursing staff employed within Anesthesiology and Intensive Care Departments of the Medical University of Warsaw network.\n* No prior experience with the use of Mental Rehearsal techniques in performing emergency cricothyroidotomy.\n* Informed consent.\n\nExclusion Criteria:\n\n* Medical personnel involved in the training process of study participants in emergency cricothyroidotomy, including instructors, assisting staff, and examiners.\n* Previous experience with the use of Mental Rehearsal techniques for acquiring competencies in performing emergency cricothyroidotomy.\n* Lack of informed consent.",{"count":114,"type":23},60,[26],"Medical staff at the clinic will participate in standard cricothyroidotomy training supplemented with structured mental rehearsal exercises in order to evaluate the usefulness and effectiveness of this approach as a training tool.",[118,119,120,121],"Difficult Airway","Medical Training","Airway Management","Cricothyroidotomy",[123,124,125,121,120,126],"Mental Rehearsal","Mental Training","eFONA (Emergency Front of Neck Airway)","Critical care","NOT_YET_RECRUITING","2026-06-01",{"date":130,"type":43},"2026-06-04",{"date":132,"type":23},"2026-06-08",{"date":134,"type":23},"2028-05-01",{"name":49,"class":50},{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":18,"minAge":20,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":24,"phases":145,"briefSummary":146,"conditions":147,"keywords":152,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":51},"100632851","effect-of-preoperative-oral-carbohydrate-loading-on-postoperative-outcomes-in-liver-transplant-patients-100632851","NCT07519057","Effect of Preoperative Oral Carbohydrate Loading on Postoperative Outcomes in Liver Transplant Patients","Effect of Preoperative Oral Carbohydrate Loading on Postoperative Outcomes in Liver Transplant Patients: A Randomized, Placebo-Controlled Trial","Inclusion Criteria:\n\n* age ≥ 18 years\n* elective liver transplantation at the Department of General, Transplant, and Liver Surgery, Medical University of Warsaw\n* grafts from brain-dead donors\n* MELD score \\\u003C35\n\nExclusion Criteria:\n\n* acute liver failure\n* insulin-dependent diabetes mellitus\n* gastroparesis\n* mechanical bowel obstruction\n* liver retransplantation within less than 6 months of the primary transplant",{"count":144,"type":23},434,[26],"The aim of the study is to evaluate the effect of preoperative oral carbohydrate loading on postoperative outcomes in liver transplant recipients. The results of this study may contribute to improving recovery after liver transplantation and shortening postoperative hospital stay in these patients.\n\nParticipants will be randomly assigned to either the study group or the control group. Patients assigned to the study group will receive 400 mL of a carbohydrate beverage (Nutricia preOp®), to be consumed up to 2 hours before the anesthesia induction. Patients assigned to the control group will receive 400 mL of a placebo administered in an identical manner as in the study group. Participants will not be informed which group they have been assigned to.\n\nIn the postoperative period, routine laboratory and imaging tests will be performed, and their results will be used to assess the effects of the intervention. Follow-up of the patient's clinical course is planned for up to 30 days after surgery. The schedule of follow-up visits will not differ from standard clinical practice.",[148,149,150,151],"Liver Transplantation","Liver Transplant","Liver Transplant Surgery","End Stage Liver Disease",[153,154,155,148,149,156,157],"Preoperative Oral Carbohydrate Loading","POCL","Nutricia PreOp","Carbohydrate drink","Preoperative Carbohydrate Loading",{"date":159,"type":43},"2026-06-03",{"date":161,"type":43},"2026-05-27",{"date":163,"type":23},"2028-08",{"name":49,"class":50},{"id":166,"slug":167,"hasResults":12,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":12,"sex":18,"minAge":20,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":24,"phases":175,"briefSummary":176,"conditions":177,"keywords":183,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":51},"100624758","comparison-of-skin-closure-techniques-in-oncological-neurosurgical-procedures-intradermal-running-suture-versus-transdermal-interrupted-sutures-100624758","NCT07413796","Comparison of Skin Closure Techniques in Oncological Neurosurgical Procedures: Intradermal Running Suture Versus Transdermal Interrupted Sutures","Prospective Randomized Controlled Trial of Skin Closure Techniques in Oncological Cranial Neurosurgery: Interrupted Transdermal Sutures and Running Intradermal Suture.","NEURO-SUTURE","Inclusion Criteria:\n\n* Male or female at least 18 years old\n* Qualified for a craniotomy due to supratentorial intracranial tumor\n\nExclusion Criteria:\n\n* Revision surgery due to recurrent brain tumor\n* Emergency neurosurgical procedure\n* Scalp incision involving glabrous skin (e.g. forehead) or facial regions (e.g. eyebrow)",{"count":174,"type":23},382,[26],"The purpose of this study is to compare two commonly used methods of closing the skin after surgery for an intracranial tumor. Skin closure is one of the most important steps in neurosurgical procedures, as it has a major influence on how well the wound heals. In patients with brain tumors, proper wound healing is especially important because it may affect how soon additional treatments, such as radiotherapy or chemotherapy, can be started.\n\nThere are different ways to close the skin after surgery, including running sutures and interrupted sutures. Both methods are widely used and considered safe. However, in oncological neurosurgery, there is limited scientific evidence comparing their effects, and the choice of technique is often based on the surgeon's personal experience. In this study, investigators will compare skin closure using running absorbable sutures with interrupted non-absorbable sutures. Investigators will evaluate how well, depending on used suturing methods, the wound heals and how often wound-related complications occur, such as infection, separation of the wound edges, or leakage of cerebrospinal fluid. Investigators believe that the results of this study will help improve wound care in patients undergoing neurosurgical treatment for brain tumors and, as a result, may contribute to better recovery and overall quality of life.",[178,179,180,181,182],"Brain Tumor Adult","Brain Tumor Benign","Meningioma","Glioma","Glioblastoma",[184,185,186,187,188],"skin closure","brain tumor","intracranial tumor","glioma","meningioma","2026-05-19",{"date":191,"type":43},"2026-05-20",{"date":193,"type":43},"2026-02-01",{"date":195,"type":23},"2028-05",{"name":49,"class":50},{"id":198,"slug":199,"hasResults":12,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":12,"sex":18,"minAge":20,"maxAge":4,"enrollmentInfo":205,"targetDuration":207,"studyType":62,"phases":4,"briefSummary":208,"conditions":209,"keywords":212,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":51},"100624596","analysis-of-cerebrospinal-fluid-leakage-after-surgery-for-intracranial-tumors-100624596","NCT07411690","Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial Tumors","Cerebrospinal Fluid Leak Incidence, Management and Risk Factor After Supratentorial Craniotomy for Intracranial Tumors: a Prospective Observational Study.","CSF-IMR","Inclusion Criteria:\n\n* Male or female at least 18 years old\n* Qualified for a craniotomy due to supratentorial intracranial tumor\n\nExclusion Criteria:\n\n* Revision surgery due to recurrent brain tumor\n* Emergency neurosurgical procedure",{"count":206,"type":23},200,"6 Weeks","Cerebrospinal fluid is a clear fluid that surrounds and protects the brain. During surgery for brain tumors, neurosurgeons often need to open the covering of the brain (the dura) to reach the tumor. At the end of the operation, this covering is carefully closed again. In some cases, the closure might not be completely adequate leading to cerebrospinal fluid leak. This leakage may collect under the scalp or flow out through the surgical wound. When this happens, the surgical wound may not heal properly, and the risk of infection can increase. These complications can delay recovery and may postpone additional treatments, such as radiotherapy or chemotherapy, that are often needed after brain tumor surgery. Although cerebrospinal fluid leakage is less common after supratentorial craniotomy (surgery on the upper part of the brain) than after other types of brain surgery, it remains a challenging complication and has not been well studied in this group of patients. The aim of this study is to determine how often cerebrospinal fluid leakage occurs after supratentorial craniotomy for intracranial tumors, identify factors that increase the risk of leakage, and evaluate how these leaks are managed. Understanding these factors may help reduce the occurrence of cerebrospinal fluid leakage and improve postoperative recovery in the future.",[178,179,210,211,182,181,180],"CerebroSpinal Fluid (CSF) Leak","Craniotomy",[186,213,214,187,188],"cerebrospinal fluid leak","supratentorial craniotomy",{"date":216,"type":43},"2026-05-22",{"date":218,"type":43},"2026-02-03",{"date":220,"type":23},"2028-04",{"name":49,"class":50},{"id":223,"slug":224,"hasResults":12,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":85,"sex":18,"minAge":20,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":231,"conditions":232,"keywords":236,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":51},"100638301","assessment-of-lvot-vti-in-healthy-volunteers-100638301","NCT07600931","Assessment of LVOT VTI in Healthy Volunteers","Reproducibility, Intra- and Inter-Observer Variability of Bedside Cardiac Ultrasound Measurements in the Assessment of Hemodynamic Parameters in Healthy Volunteers","Inclusion Criteria:\n\n* Age \\> 18 years,\n* Medical student at Medical University of Warsaw or licensed physician.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years,\n* Prior experience in performing cardiac ultrasound examinations, including acquisition of apical five- and three-chamber views and Doppler measurements of LVOT VTI.",{"count":230,"type":23},30,"Healthy subjects will have transthoracic echocardiography evaluation of Left Ventricular Outflow Tract Velocity-Time Integral (LVOT VTI) performed by operators after brief training.",[233,234,235],"Hemodynamic Assessment","Bedside Ultrasonography","Point of Care Ultrasound (POCUS)",[233,237,234,238,126],"Velocity-Time Integral","Point of care ultrasound","2026-05-14",{"date":216,"type":43},{"date":242,"type":23},"2026-05-11",{"date":244,"type":23},"2027-01",{"name":49,"class":50},{"id":247,"slug":248,"hasResults":12,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":252,"eligibilityCriteria":253,"healthyVolunteers":12,"sex":18,"minAge":20,"maxAge":4,"enrollmentInfo":254,"targetDuration":256,"studyType":62,"phases":4,"briefSummary":257,"conditions":258,"keywords":263,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":51},"100635640","outpatient-midline-catheter-in-patients-receiveing-lidocaine-infusion-series-100635640","NCT07555314","Outpatient Midline Catheter in Patients Receiveing Lidocaine Infusion Series.","Outpatient Midline Catheter in Patients Receiveing Lidocaine Infusion Therapy. A Prospective, Observational Study.","Midline Lid","Inclusion Criteria:\n\n* Patients qualified for lidocaine infusion therapy due to the chronic pain\n* Able to provide consent\n* ≥18 years of age\n\nExclusion Criteria:\n\n* Lack of patient consent",{"count":255,"type":23},500,"10 Days","This study will assess the efficacy, safety and practicality of using midline catheters for repeated intravenous lidocaine infusions in an outpatient pain management setting. Adult patients requiring serial lidocaine infusions for chronic pain will be enrolled and receive treatment through midline catheters over ten sessions.\n\nThe study will investigate if the midline catheters are a safe and effective option for delivering repeated lidocaine infusions in the outpatient setting, offering a balance between ease of placement, acceptable complication risk and good patients' comfort.",[259,260,261,262],"Midline Catheter","Lidocaine Infusion","Chronic Pain","Outpatient",[264,265,266,267],"midline catheter","lidocaine infusion","chronic pain","outpatient","2026-04-21",{"date":270,"type":43},"2026-04-29",{"date":272,"type":23},"2026-04-20",{"date":274,"type":23},"2028-06-01",{"name":49,"class":50},{"id":277,"slug":278,"hasResults":12,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":282,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":24,"phases":286,"briefSummary":287,"conditions":288,"keywords":294,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":303,"leadSponsor":305,"locationsCount":51},"100632301","routine-intraoperative-white-test-for-bile-leak-detection-in-liver-resection-100632301","NCT07511907","Routine Intraoperative White Test for Bile Leak Detection in Liver Resection","Routine White Test for Early Detection of Bile Leak in Elective Liver Resection - A Study Protocol for Randomized Controlled Trial (DELiveR Trial).","DELiveR","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Undergoing elective liver surgery (regardless its modality): a) major hepatectomy OR b) minor hepatectomy (anatomic liver resection or non-anatomic liver resection).\n* Possibility of performing the WT: intraoperative, simultaneous cholecystectomy or prior cholecystectomy with identifiable cystic stump allowing bile duct access.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Undergoing intraoperative hepaticojejunostomy.\n* Previous cholecystectomy without accessible cystic stump.\n* Unresectable disease found intraoperatively.\n* Allergy to SMOFlipid 5% components.\n* Pregnancy or lactation.\n* Emergency liver resection.\n* Refusal for participation in trial.",{"count":285,"type":23},260,[26],"Bile leakage (BL) remains one of the most frequent complications following liver resection and is associated with increased postoperative morbidity and mortality, higher reintervention rates, prolonged hospital stay, and increased healthcare costs. Effective intraoperative identification and closure of open bile ducts may reduce the risk of postoperative BL. The White Test, which involves retrograde injection of a lipid emulsion into the biliary tree, enables active detection of bile leaks during surgery; however, its routine use has not been established in randomized clinical trials across all types of liver resection.\n\nThis is a single-center, prospective, randomized, parallel-group, single-blinded superiority trial designed to evaluate the effectiveness of routine intraoperative use of the White Test compared with standard intraoperative bile leak detection using a white gauze test. Adult patients undergoing elective liver resection (major or minor, including both anatomic and non-anatomic resections) who meet eligibility criteria will be enrolled after providing written informed consent.\n\nParticipants will be randomized in a 1:1 ratio to either the intervention group (White Test) or the control group (standard gauze test), using stratified block randomization according to the type of resection (major vs minor). Allocation will be concealed using sequentially numbered, opaque, sealed envelopes. Patients will remain blinded to group assignment, while the operating surgeon cannot be blinded due to the nature of the intervention.\n\nIn the intervention group, following completion of liver parenchymal transection and achievement of hemostasis, the cystic duct stump will be identified and cannulated. The distal bile duct will be temporarily occluded, and 10-20 mL of lipid emulsion will be injected retrogradely into the biliary tree. The transection surface will be inspected for leakage of the white emulsion. Identified leaks will be managed by ligation or suturing, and the test may be repeated until no further leakage is observed. In the control group, bile leak detection will be performed by applying sterile white gauze to the transection surface with visual inspection, followed by suturing of identified leaks as needed.\n\nAll patients will have intra-abdominal drainage placed at the resection site. Drain fluid bilirubin concentration will be measured on postoperative day three. Patients will be followed for 30 days after surgery.\n\nThe primary outcome is the incidence of postoperative bile leakage within 30 days, defined according to the International Study Group of Liver Surgery (ISGLS) criteria. Secondary outcomes include severity of bile leakage (ISGLS grades A-C), postoperative morbidity (Clavien-Dindo classification), need for postoperative interventions (endoscopic, radiological, or surgical), intensive care unit (ICU) admission and length of ICU stay, and total hospital length of stay.\n\nThe primary analysis will follow the intention-to-treat principle and will be performed separately within strata defined by resection type (major vs minor). Secondary and subgroup analyses will be considered exploratory. No formal interim analysis is planned; however, patient safety will be continuously monitored throughout the study.\n\nThe results of this trial are expected to clarify the role of routine intraoperative White Test in liver surgery and its potential to reduce postoperative bile leakage and improve clinical outcomes.",[289,290,291,292,293],"Bile Leak","Bile Leakage","Liver Resection","Hepatectomy","Bile Duct Disorder",[295,296,297,298],"liver resection","hepatectomy","bile ducts","white test","2026-04-11",{"date":301,"type":43},"2026-04-15",{"date":69,"type":23},{"date":304,"type":23},"2028-10-01",{"name":49,"class":50},{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":12,"sex":18,"minAge":20,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":24,"phases":315,"briefSummary":316,"conditions":317,"keywords":322,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":51},"100633115","imageless-navigation-versus-image-based-navigation-in-robotic-assisted-total-knee-arthroplasty-for-knee-osteoarthritis-100633115","NCT07522489","Imageless Navigation Versus Image-Based Navigation in Robotic-Assisted Total Knee Arthroplasty for Knee Osteoarthritis","Outcomes of Robotic-Assisted Total Knee Arthroplasty With Imageless Navigation Versus Image-Based Navigation: A Randomised, Single-Blinded, Non-Inferiority Trial","Inclusion Criteria:\n\n1. Symptomatic, radiologically confirmed advanced osteoarthritis of the knee.\n2. Patients referred for primary robotic-assisted total knee arthroplasty.\n3. Patients in whom a correctly performed radiograph with designated sensors has confirmed the possibility of performing robotic-assisted total knee arthroplasty with image-based navigation.\n4. Patients capable of giving informed consent to participate in the study and willing to attend all follow-up visits.\n\nExclusion Criteria:\n\n1. No informed consent for the surgery.\n2. No informed consent for taking part in the study.\n3. Pregnancy.\n4. Active infections.\n5. Diagnosed comorbidities: autoimmune arthritis, malignant tumors, serious neurological disorders affecting a reliable functional outcome measurement (e.g., severe stroke, severe Parkinson's disease).",{"count":314,"type":23},146,[26],"The goal of this clinical trial is to learn if imageless navigation is not inferior to image-based navigation in robotic-assisted total knee arthroplasty (RA-TKA) for treating patients with knee osteoarthritis.\n\nThe main questions the study aims to answer are:\n\n1. Does imageless procedure provide functional results comparable to those of image-based navigation?\n2. Are there differences in postoperative complications patients may experience after RA-TKA with imageless and image-based navigation? Researchers will compare imageless navigation with image-based navigation used in total knee arthroplasty to assess whether imageless navigation is comparable for the treatment of knee osteoarthritis.\n\nParticipants will:\n\n1. Answer survey questions about knee pain and function before RA-TKA.\n2. Undergo RA-TKA with imageless navigation or image-based navigation.\n3. Visit the Clinic after 6 months and 12 months after surgery for checkups and to answer the same survey questions about postoperative knee pain and function.",[318,319,320,321],"Osteoarthritis (OA) of the Knee","Knee Pain Arthritis","Total Knee Arthroplasty (TKA)","Robotic Assisted Arthroplasty",[323,324,325,326,327],"Knee Osteoarthritis","Robotic-Assisted Total Knee Arthroplasty","Patient Reported Outcome Measures","Imageless Navigation","Image-based Navigation","2026-04-07",{"date":330,"type":43},"2026-04-13",{"date":332,"type":23},"2026-05",{"date":334,"type":23},"2029-01",{"name":49,"class":50},{"id":337,"slug":338,"hasResults":12,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":342,"eligibilityCriteria":343,"healthyVolunteers":12,"sex":18,"minAge":344,"maxAge":4,"enrollmentInfo":345,"targetDuration":4,"studyType":24,"phases":347,"briefSummary":348,"conditions":349,"keywords":351,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":4},"100632598","tavi-without-on-site-cardiac-surgery-in-poland-a-randomized-multicenter-trial-protocol-100632598","NCT07515768","TAVI Without On-Site Cardiac Surgery in Poland: A Randomized Multicenter Trial Protocol","Transcatheter Aortic Valve Implantation Without On-Site Cardiac Surgery in Poland: Protocol for a Multicenter Prospective Randomized Open-label Clinical Trial","NOSCAR-TAVI","Inclusion Criteria:\n\n* Severe degenerative aortic valve stenosis with echocardiography derived criteria: mean gradient ≥40 mmHg or jet velocity ≥4.0 m\u002Fs or an aortic valve area (AVA) of ≤1 cm2 (or AVA index \\\u003C0.6 cm2\u002Fm2)\n* Symptomatic due to aortic valve stenosis as demonstrated by NYHA Functional Class ≥ II.\n* Suitable for percutaneous transfemoral access\n* Age ≥70 years\n\nExclusion Criteria:\n\n* Prior aortic valve replacement\n* Bicuspid aortic valve on pre-procedural CT\n* Contraindication to femoral access\n* Other imaging features indicating increased procedural risk (extremely horizontal aorta, severe aortic root dilatation, aortic annulus outside the range of commercially available devices, high coronary risk occlusion)\n* Life expectancy \\\u003C12 month or active malignancy\n* Active endocarditis","70 Years",{"count":346,"type":23},404,[26],"Aortic stenosis (AS) represents the most prevalent acquired valvular heart disease in European populations, and transcatheter aortic valve implantation (TAVI) has become the dominant treatment modality for patients with symptomatic severe AS. The latest 2025 ESC guidelines have broadened age-related eligibility, while the procedure still continues to be limited to centres with cardiac surgery on-site (CSOS). This limitation is in place, despite the very low rate of complications requiring emergent surgical conversion. This subsequently, may constrain procedural capacity and contribute to prolonged waiting times, which in turn are associated with increased pre-procedural mortality and heart failure-related hospitalizations. This prospective randomized open-label clinical trial aims to evaluate the safety and feasibility of performing TAVI in selected pilot centers operating without on-site cardiac surgery department (no-CSOS). Selected patients with severe native AS deemed suitable for transfemoral TAVI by a Heart Team will be enrolled. No-CSOS centers must meet predefined criteria, including operators experience, hybrid operating room availability, on-site vascular surgery availability, and established rapid transfer pathways to CSOS centers. The primary endpoint of the study is early 30-day safety based on VARC-3 criteria; secondary endpoints include additional composite outcomes. Patients will be randomly assigned in a 1:1 ratio using a central Web-based system to undergo TAVI either at a CSOS or non-CSOS site. A total of 404 patients (202 per group) is required. The study will inform national strategies and contribute to defining contemporary safety standards for TAVI delivery in no-CSOS centres.",[350],"Aortic Stenosis",[352,353],"aortic stenosis","transcatceter aortic valve implantation","2026-03-31",{"date":328,"type":43},{"date":357,"type":23},"2026-09-01",{"date":359,"type":23},"2030-09-01",{"name":49,"class":50},{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":12,"sex":18,"minAge":20,"maxAge":368,"enrollmentInfo":369,"targetDuration":4,"studyType":24,"phases":371,"briefSummary":372,"conditions":373,"keywords":376,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":390},"100630521","local-targeted-therapy-with-alpha-emitter-225acac-dota-sp-tat-in-newly-diagnosed-glioma-who-g3-g4-100630521","NCT07488754","Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4)","Medical Experiment - Assessment of Efficacy & Safety of Local, Targeted Therapy With Neuropeptide Labelled With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) as Supplementary Therapy Following Standard Treatment Of Glioma (WHO G3-G4)","Inclusion Criteria:\n\n* age 18-80;\n* histologically confirmed diffuse glioma (CNS WHO G3-G4);\n* after standard treatment with biopsy or resection, radiotherapy and\u002For chemotherapy;\n* no sign of progression or radiation necrosis;\n* functional state \\>70 according to Karnofsky's performance scale (KPS);\n* ability to give informed consent to participate in the study.\n\nExclusion Criteria:\n\n* low-grade glioma;\n* progression or recurrence defined as: deterioration of the patient's condition according to the Karnofsky Performance Scale, worsening of neurological function, progressive neurological deficit, need to initiate or increase corticosteroid dose by \\>50%, progression or recurrence assessed on MRI (RANO criteria);\n* radiation-induced necrosis secondary to radiotherapy; may occur within the first 3 months after radiotherapy (exception: a patient after resection of radiation necrosis - not earlier than 4 weeks post-surgery, after a follow-up MRI);\n* need for emergency surgery (e.g., acute increase in intracranial pressure);\n* significant postoperative complications, e.g., KPS \\\u003C 70, wound infection, cerebrospinal fluid leak;\n* leak into the ventricular system \\>10% during the catheter patency check;\n* open\u002Fventricle-connected resection cavity;\n* catheter obstruction;\n* estimated life expectancy under 3 months;\n* patients without preserved logical\u002Fverbal contact;\n* lack of cooperation from the patient;\n* inability to give informed, voluntary consent to participate in the study;\n* patients enrolled in another medical trial;\n* patients who received any other investigational drug within 1 month prior to the first dose;\n* prior treatment with \\[225Ac\\]Ac-DOTA-SP;\n* breastfeeding or pregnant women;\n* severe comorbid organ diseases that, in the Investigator's opinion, significantly increase the procedural risk.","80 Years",{"count":370,"type":23},35,[26],"Brain tumors account for 1.35% of all cancers and cause 2.2% of cancer-related deaths. Gliomas are the most common type, comprising 40-90% of central nervous system tumors in different age groups. The incidence of malignant gliomas is approximately 0.5-2 per 100,000 people annually. Standard treatments include surgical resection, radiotherapy, and chemotherapy, yet overall survival remains low, typically 1-3 years post-diagnosis. The study highlights the pressing need for novel treatment strategies, particularly given the infiltrative nature of gliomas and the potential for targeted therapies using neuropeptides.The aim of this study is to assess the efficacy and safety of local targeted therapy with \\[225Ac\\]Ac-DOTA-SP in newly diagnosed glioblastoma following standard treatment.It is an interventional study without a control group, initiated by the researcher. Patients included are aged 18-80 with WHO G3-G4 glioma post-first-line treatment, not requiring immediate surgery and meeting specific MRI criteria.Patients will receive a maximum of six cycles of \\[225Ac\\]Ac-DOTA-SP, involving pre-treatment assessments, local administration of the agent after ensuring catheter patency, and continuous monitoring. Blood tests and neurological evaluations will be performed regularly.Outcome will be assessed by measuring overall survival (OS) and progression-free survival (PFS). The study anticipates improvements in both OS and PFS when compared to current treatments, contributing to critical insights into targeted alpha therapy's effectiveness in glioblastoma.Treatment with \\[225Ac\\]Ac-DOTA-SP previously indicated few significant side effects, primarily transient issues like seizures. Patients will be closely monitored throughout the study to identify any adverse effects promptly.The estimated study duration is three years, with biological material collected for histopathological and genetic analysis during surgical reoperation.Data will be anonymized to protect patient confidentiality, stored securely, and made available only for the scope of the study.Led by Prof. Przemysław Kunert, the research team includes multiple co-investigators from neurosurgery and nuclear medicine departments.",[182,374,375],"High-Grade Glioma (WHO III-IV)","Glioblastoma (GBM)",[377,378,379,380,381],"alpha emitter","glioblastoma","local therapy","225-Ac","high-grade glioma","2026-03-30",{"date":384,"type":43},"2026-04-06",{"date":386,"type":43},"2025-10-01",{"date":388,"type":23},"2028-09",{"name":49,"class":50},2,{"id":392,"slug":393,"hasResults":12,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":4,"eligibilityCriteria":397,"healthyVolunteers":85,"sex":18,"minAge":20,"maxAge":4,"enrollmentInfo":398,"targetDuration":4,"studyType":24,"phases":400,"briefSummary":401,"conditions":402,"keywords":406,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":426,"locationsCount":51},"100623612","use-of-augmented-reality-glasses-and-noise-cancelling-headphones-to-reduce-dental-anxiety-in-adult-patients-100623612","NCT07398898","Use of Augmented Reality Glasses and Noise-Cancelling Headphones to Reduce Dental Anxiety in Adult Patients","Use of New Technologies in Dentistry","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Qualified for one of the following dental procedures: supragingival scaling, curettage, tooth extraction, or caries cavity preparation and restoration\n* Provided written informed consent\n* Agreed to random allocation to one of the study groups\n* Able to understand and complete the STAI questionnaire and VAS pain scale\n\nExclusion Criteria:\n\n* Acute dental pain at the time of the procedure\n* Teeth qualified for resection\n* Pregnancy\n* Diagnosis of cerebral palsy\n* Epilepsy with seizures in the past 6 months\n* Use of hearing aids\n* Severe vision impairment\n* Non-cooperative behavior or inability to understand the study questionnaires\n* Absence on the scheduled procedure date",{"count":399,"type":23},250,[26],"This study investigates whether new audiovisual technologies can help reduce anxiety and stress experienced by adult patients during dental procedures. Dental fear and anxiety are common barriers to receiving proper oral care. This randomized controlled trial aims to explore whether the use of specific devices-augmented reality (AR) glasses and noise-cancelling (ANC) headphones-can improve patient comfort and decrease physiological signs of stress during dental treatment.\n\nParticipants in this study will undergo a standard dental procedure. In addition, they will be randomly assigned to one of three groups: a control group (no audiovisual intervention), a group using ANC headphones that play relaxing music during the procedure, or a group using AR glasses that display relaxing visual scenes along with the same music.\n\nBefore the procedure, each participant will complete a psychological questionnaire (STAI) to assess their level of anxiety. During the procedure, physiological stress will be monitored using sensors that track parameters such as skin conductance (GSR) and heart rate. After the treatment, patients will be asked to rate their pain level and describe their experience with or without the audiovisual intervention.\n\nThe goal is to better understand the effectiveness of non-pharmacological methods in reducing anxiety and stress in adult dental patients. Participation in the study is entirely voluntary and will not affect the quality or availability of dental care. Patients may withdraw at any time without consequences. The study also collects basic demographic information and patient feedback to evaluate potential factors that may influence anxiety levels.\n\nBy testing new immersive tools such as AR glasses and ANC headphones in a real clinical setting, this research may contribute to improving patient well-being and enhancing the dental care experience.",[403,404,405],"Dental Anxiety","Music Therapy","Oral Surgical Procedures",[407,408,409,410,411,412,413,414,415,416,417,418],"dental anxiety","Music therapy","augmented reality","active noise cancelling","maxillofacial surgery","Dental phobia","audiovisual distraction","dental fear","perioperative anxiety","STAI","galvanic skin response","relaxation techniques","2026-03-25",{"date":421,"type":43},"2026-03-27",{"date":423,"type":43},"2026-03-01",{"date":425,"type":23},"2026-06-30",{"name":49,"class":50},{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":4,"eligibilityCriteria":433,"healthyVolunteers":12,"sex":18,"minAge":434,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":24,"phases":436,"briefSummary":437,"conditions":438,"keywords":4,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":51},"100631283","prp-injection-into-the-sacroiliac-joint-after-ipsilateral-tha-effects-on-early-recovery-and-function-sij-tha-randomized-trial-100631283","NCT07498660","PRP Injection Into the Sacroiliac Joint After Ipsilateral THA: Effects on Early Recovery and Function (SIJ-THA Randomized Trial)","Effect of Platelet-Rich Plasma Injection Into the Sacroiliac Joint After Ipsilateral Total Hip Arthroplasty on Early Rehabilitation and Patient Function: A Randomized Trial (SIJ-THA Trial)","Inclusion Criteria:\n\n* primary osteoarthritis of the hip;\n* qualification for elective total hip arthroplasty (THA);\n* age ≥45 years;\n* written informed consent;\n* ability to understand Polish.\n\nExclusion Criteria:\n\n* prior surgical treatment of the hip or sacroiliac joint;\n* malignancy;\n* developmental dysplasia of the hip;\n* rheumatologic diseases (rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis);\n* neurological or psychiatric disorders;\n* allergy to local anesthetics.","45 Years",{"count":114,"type":23},[26],"The study is an interventional, randomized, open-label (non-blinded), placebo-controlled trial. Preoperatively, patients scheduled for primary total hip arthroplasty (THA) will undergo a clinical examination in the Orthopaedic Department. Clinical tests will be performed to confirm sacroiliac joint (SIJ) dysfunction on the operated side. In addition, low-dose computed tomography (CT) will be used to assess structural changes in the SIJ.\n\nAll patients will complete patient-reported outcome measures related to the hip joint, including the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and the Harris Hip Score (HHS), as well as SIJ-related assessments, including the Oswestry Disability Index (ODI). Pain intensity will be assessed using the Visual Analogue Scale (VAS).\n\nFollowing THA, patients will be randomly allocated into two groups during their hospital stay. In the intervention group, platelet-rich plasma (PRP) will be injected into the sacroiliac joint, whereas the control group will receive an injection of normal saline. All injections will be performed in the operating theatre.\n\nAt discharge, patients will be scheduled for follow-up visits at 2, 6, and 12 weeks postoperatively. At each follow-up, patient-reported outcomes will be collected, including WOMAC and HHS for hip function, ODI for SIJ-related disability, and VAS for pain assessment of both the hip and sacroiliac joint.",[439,440,441,442],"Osteoarthitis","Sacro Iliac Joint Pain","Hip Arthroplasty, Total","Sacro-Iliac Spondylosis","2026-03-23",{"date":421,"type":43},{"date":446,"type":23},"2026-04-01",{"date":448,"type":23},"2028-03-31",{"name":49,"class":50},{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":85,"sex":18,"minAge":20,"maxAge":457,"enrollmentInfo":458,"targetDuration":4,"studyType":24,"phases":460,"briefSummary":461,"conditions":462,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":468,"leadSponsor":470,"locationsCount":51},"100623928","impact-of-root-surface-conditioning-with-erythritol-air-polishing-and-hand-instrumentation-on-recession-coverage-using-the-modified-tunnel-technique-and-subepithelial-connective-tissue-graft-100623928","NCT07403006","Impact of Root Surface Conditioning With Erythritol Air Polishing and Hand Instrumentation on Recession Coverage Using the Modified Tunnel Technique and Subepithelial Connective Tissue Graft.","Impact of Root Surface Conditioning With Erythritol Air Polishing Versus Hand Instrumentation on Recession Coverage Using the Modified Tunnel Technique and Subepithelial Connective Tissue Graft: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Multiple RT1 and\u002For RT2 gingival recessions, symmetrical and bilateral, with a minimum height of ≥ 1 mm\n* Full-mouth plaque score (FMPS) \\\u003C 15% (assessed on four surfaces per tooth)\n* Full-mouth bleeding on probing (FMBOP) \\\u003C 15% (assessed on four surfaces per tooth)\n* Detectable cemento-enamel junction (CEJ)\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* RT3 gingival recessions\n* Gingival recessions affecting second and third molars\n* Systemic or infectious diseases that may impair wound healing, including active malignancy, diabetes mellitus with HbA1c \\> 7.0%, history of head and neck radiotherapy, true xerostomia, and HIV\u002FAIDS\n* Cervical caries, non-carious cervical lesions, or Class V restorations interfering with the CEJ\n* Active periodontitis\n* Use of medications affecting periodontal tissues or wound healing, including systemic corticosteroids, immunosuppressants, isotretinoin, bisphosphonates, and monoclonal antibodies with immunosuppressive, antiresorptive, or antiangiogenic effects\n* Smoking\n* Pregnancy or breastfeeding","60 Years",{"count":459,"type":23},20,[26],"This study aims to evaluate whether the method of root surface preparation influences surgical outcomes. It will assess whether manual root instrumentation can be replaced by a less invasive erythritol air-polishing technique.",[463],"Gingival Recession","2026-03-09",{"date":466,"type":43},"2026-03-10",{"date":464,"type":43},{"date":469,"type":23},"2027-07",{"name":49,"class":50},{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":18,"minAge":20,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":479,"conditions":480,"keywords":484,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":495,"leadSponsor":497,"locationsCount":51},"100619684","molecular-mechanisms-underlying-hip-and-knee-osteoarthritis-in-patients-undergoing-primary-elective-arthroplasty-100619684","NCT07347821","Molecular Mechanisms Underlying Hip and Knee Osteoarthritis in Patients Undergoing Primary Elective Arthroplasty","Inclusion Criteria:\n\n* 18 years old and more\n* patient qualified for primary TKA or primary THA\n* patient diagnosed with hip or knee osteoarthritis\n* a complete set of tissues of good quality and volume is available\n* does not meet the exclusion criteria.\n\nExclusion Criteria:\n\n* lack of written consent to participate in the study or surgery\n* any private or professional relationship with the Investigators\n* genetic connective tissue diseases (e.g., Ehlers-Danlos syndrome and others)\n* genetic metabolic diseases (e.g., gout and others)\n* genetic diseases affecting the anatomy of the operated joint (e.g., dysplasia and others)\n* previous surgeries altering the anatomy of the examined joint (e.g., periacetabular osteotomy, unicompartmental endoprosthesis, and others)\n* patients undergoing revision after THA\u002FTKA\n* autoimmune diseases in the patient's medical history\n* traumatic injury to the hip or knee joint\n* previous participation in the study.",{"count":478,"type":23},1000,"The aim of this observational study is to determine content of rare metals and other elements, along with the levels of selected immunological parameters, in the tissue of the hip or knee joint in the course of degenerative diseases. Determining potential disturbances in the levels or functions of these parameters may in the future contribute to improving treatment - for example, through supplementation of deficient metals or modulation at the immunological level. The main question it aims to answer is:\n\nAre selected rare metals, trace elements and other selected immunological parameters lowered in the tissue of the hip or knee joint as well as in serum in the course of osteoarthritis?",[481,320,482,483],"Total Hip Arthroplasty (THA)","Hip Osteoarthritis","Knee Osteoarthristis",[485,486,487,488,489,490],"Total Knee Replacement","Total Hip Replacement","Trace Elements","Osteoarthritis","Cytokines","Oxidative Stress","2026-01-08",{"date":493,"type":43},"2026-01-16",{"date":101,"type":43},{"date":496,"type":23},"2028-12",{"name":49,"class":50},{"id":499,"slug":500,"hasResults":12,"nctId":501,"briefTitle":502,"officialTitle":502,"acronym":503,"eligibilityCriteria":504,"healthyVolunteers":12,"sex":18,"minAge":505,"maxAge":506,"enrollmentInfo":507,"targetDuration":4,"studyType":24,"phases":509,"briefSummary":510,"conditions":511,"keywords":513,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":522},"100550568","the-effect-of-a-multispecies-probiotics-on-autism-symptoms-in-children-100550568","NCT06448767","The Effect of a Multispecies Probiotics on Autism Symptoms in Children","PROBAUT","Inclusion Criteria:\n\n1. Diagnosis of ASD according to the Diagnostic and Statistical Manual of Mental Disorders, the fifth edition (DSM-5) or International Classification of Diseases, Tenth Revision (ICD-10).\n2. Children either not taking any medication or receiving the same medication for the last 2 months.\n3. Patients, or their parents\u002Fcaregivers, are willing to provide written informed consent, proceed with nutritional supplements throughout the 3-month trial, refrain from starting any kind of special diet for the duration of the study, and complete the questionnaires at two time points during the study.\n\nExclusion Criteria:\n\n1. Use of antibiotics in the previous 2 months before enrolling (excluding topical antibiotics).\n2. Use of probiotics or synbiotics within the previous 2 months.\n3. History of intolerance or allergy to probiotics, synbiotics or any other study product component.\n4. Surgery with bowel resection or short bowel syndrome.\n5. Children with severe immunodeficiency.","7 Years","15 Years",{"count":508,"type":23},110,[26],"In this trial, the investigators aim to evaluate the impact of a multispecies probiotic consisting of Bacillus subtilis W201, Bifidobacterium infantis W17, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus rhamnosus W140, Lactococcus lactis W19, Propionibacterium freudenreichii W200, on the severity of autism symptoms, quality of life, gastrointestinal symptoms, sleep disturbances, parental stress levels and urinary p-cresol concentrations in children with Autism Spectrum Disorder aged 7 to 15 years.",[512],"Autism Spectrum Disorder",[512,514],"Probiotics","2026-01-05",{"date":491,"type":43},{"date":518,"type":43},"2024-08-07",{"date":520,"type":23},"2026-07-30",{"name":49,"class":50},3,{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":529,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":18,"minAge":20,"maxAge":4,"enrollmentInfo":531,"targetDuration":533,"studyType":62,"phases":4,"briefSummary":534,"conditions":535,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":544,"locationsCount":51},"100615105","duration-of-preoperative-clear-fluids-fasting-in-patients-undergoing-liver-transplant-100615105","NCT07288281","\"Duration of Preoperative Clear Fluids Fasting in Patients Undergoing Liver Transplant\"","\"Duration of Preoperative Clear Fluids Fasting in Patients Undergoing Liver Transplant. A Prospective Observational Study: the \"Timbarc-1\" a Pilot Study\"","Timbarc-1","Inclusion Criteria:\n\n* patients scheduled for elective liver transplant\n\nExclusion Criteria:\n\n* patients unable to give detailed answer on clear fluid fasting due to severe hepatic encephalopathy or cognitive impairment\n* lack of written informed consent",{"count":532,"type":23},100,"1 Day","The goal of this prospective observational study is to report the duration of preoperative clear fluids fasting in patients undergoing liver transplant. It will also learn about the relationship between the duration of preoperative clear fluids fasting and changes in hemodynamic variables and metabolic profile at various anesthesia and transplant phases. The main questions it aims to answer are:\n\n* How long liver recipient fast from clear fluids before liver transplant?\n* Is there any relationship between the duration of preoperative clear fluids fasting and changes in blood pressure and hear rate after the induction of anesthesia?\n* Is there any relationship between the duration of preoperative clear fluids fasting and blood glucose concentration, blood lactate concentration and acid base balance during anesthesia for liver transplant?",[536,537],"Preoperative Clear Fluid Fasting","Liver Transplant Recipient","2026-01-04",{"date":540,"type":43},"2026-01-07",{"date":542,"type":43},"2025-06-01",{"date":193,"type":23},{"name":49,"class":50},{"id":546,"slug":547,"hasResults":12,"nctId":548,"briefTitle":549,"officialTitle":550,"acronym":4,"eligibilityCriteria":551,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":552,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":554,"conditions":555,"keywords":557,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":563,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":569,"locationsCount":51},"100580199","relationship-between-immunosuppressive-treatment-status-and-clinical-course-of-parkinsons-disease-100580199","NCT06834191","Relationship Between Immunosuppressive Treatment Status and Clinical Course of Parkinson's Disease","Analysis of the Relationship Between Immunosuppressive Treatment Status and Clinical Course of Parkinson's Disease","Inclusion criteria for the study group:\n\n1. Diagnosis of Parkinson's disease according to the International Parkinson and Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's disease;\n2. Immunosuppressive medication use - medication taken regularly, which we have defined as administered at a dose and frequency effective for the indicated disease, for over 12 months, systemic administration route (oral, intramuscular, subcutaneous, intravenous and inhaled); The most commonly used immunosuppressive drugs that we anticipate will be used by the study group participants include: glucocorticosteroids (GC) - budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone; calcineurin inhibitors - tacrolimus, cyclosporine; inosine monophosphate dehydrogenase (IMDH) inhibitors - azathioprine, leflunomide, mycophenolate; mammalian target of rapamycin (mTOR) inhibitors - sirolimus, everolimus; biologics - abatacept, adalimumab, anakinra, certolizumab, etanercept, infliximab, ixekizumab, natalizumab, rituximab, secukinumab, tocilizumab, ustekinumab, vedolizumab; antimetabolites - methotrexate; inclusion of participants taking immunosuppressive drugs not listed above will be considered individually;\n3. Provision of informed consent to participate in the study.\n\nInclusion criteria for the control group:\n\n1. Diagnosis of Parkinson's disease according to the International Parkinson and Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease;\n2. No history of regular use of immunosuppressive medications;\n3. Provision of informed consent to participate in the study.\n\nExclusion criteria for the study group:\n\n1. Immunosuppressive drug administration at an ad hoc basis (i.e. when symptoms occur) or irregularly (i.e. drug taken at an inappropriate dose and\u002For with a regularity ineffective for the indicated disease);\n2. Use of immunosuppressive drugs for a period of less than 12 months;\n3. Ineffective treatment of the disease requiring the use of immunosuppressive drugs (no improvement\u002Fprogression of disease symptoms);\n\nAdditional exclusion criteria for both the study and control groups:\n\n1. Advanced cancer; severe heart failure; severe renal failure; untreated autoimmune disease; active inflammation; diseases that impair drug absorption\u002Fmetabolism;\n2. Dementia;\n3. Failure\u002Finability to provide informed consent.",{"count":553,"type":23},80,"The goal of this observational study is to learn if immunosuppressive drug treatment influences the clinical course of Parkinson's disease. Recent research suggests that Parkinson's disease may have an inflammatory background. Numerous studies have identified elevated levels of pro-inflammatory markers in people with Parkinson's disease. Therefore, immunosuppressive drugs may potentially affect the course of this disease.\n\nThe investigators will recruit people with Parkinson's disease, who receive long-term immunosuppressive treatment for other chronic illnesses, into the study group. The study will also recruit people with Parkinson's disease with no history of immunosuppressive drug treatment into the control group. The main question this study aims to answer is:\n\n\\> Does immunosuppressive drug treatment slow down the onset and\u002For progression of Parkinson's disease?\n\nResearchers will compare Parkinson's disease progression rates and serum inflammatory marker levels between the study and control group, to see if immunosuppressive drug treatment influences the course of Parkinson's disease.\n\nThe study requires each participant to attend one hospital appointment. This appointment will be approximately one hour long, and will involve:\n\n1. clinical Parkinson's disease motor assessments conducted by the research team -\\> participants will be evaluated in the OFF state, meaning they will not have taken their Parkinson's disease medication the day of the assessment;\n2. completion of Parkinson's disease symptom scales;\n3. a one-time serum sample collection;\n4. detailed medical history obtainment from the participant by the research team, with a primary focus on the patient's immunosuppressive treatment history and individual clinical course of Parkinson's disease.",[556],"Parkinson Disease",[558,559,560,561,562],"Immunosuppression","Immunosuppressive treatment","cross-sectional study","observational study","Parkinson disease","2025-12-16",{"date":565,"type":43},"2025-12-23",{"date":567,"type":43},"2025-03-01",{"date":388,"type":23},{"name":49,"class":50},{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":575,"acronym":576,"eligibilityCriteria":577,"healthyVolunteers":12,"sex":18,"minAge":20,"maxAge":4,"enrollmentInfo":578,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":579,"conditions":580,"keywords":584,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":51},"100614969","sexual-activity-and-hypoglycemia-risk-in-adults-with-type-1-or-type-2-diabetes-using-insulin-therapy-and-continuous-glucose-monitoring-100614969","NCT07286500","\"Sexual Activity and Hypoglycemia Risk in Adults With Type 1 or Type 2 Diabetes Using Insulin Therapy and Continuous Glucose Monitoring\"","\"Impact of Sexual Activity on Hypoglycemia Risk in Adults With Type 1 and Type 2 Diabetes Under Insulin Therapy and Continuous Glucose Monitoring (CGM)\"","SEX-HYPO-CGM","Inclusion Criteria:\n\n* Adults aged ≥18 years.\n* Diagnosis of type 1 or type 2 diabetes.\n* Current use of a continuous glucose monitoring (CGM) system.\n* Treatment with insulin therapy in any regimen.\n* Ability to operate the CGM application and mark the start of sexual activity.\n* Willingness to participate for 3 months.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Inability to independently use the CGM application.\n* No sexual activity during the study period.\n* Withdrawal of consent at any time.\n* Any condition that, in the opinion of the investigator, prevents safe participation.",{"count":532,"type":23},"This observational study examines whether sexual activity influences the risk of hypoglycemia in adults with type 1 or type 2 diabetes treated with insulin therapy and using continuous glucose monitoring (CGM). Many patients report fear of hypoglycemia during or after sexual activity, which may affect their quality of life and willingness to engage in intimate relationships. However, no systematic research has been conducted on this topic, largely due to the sensitive nature of sexual health and the previous lack of tools to remotely monitor glucose profiles.\n\nThe study uses CGM systems (LibreView or Dexcom Clarity) to evaluate glucose changes during and up to 6 hours after sexual activity. Participants will mark the start of sexual activity in their CGM application using a neutral symbol (such as a heart icon). Data will be collected remotely through secure, certified platforms without the need for discussing details of intimate life. Glucose profiles from days with and without sexual activity will be compared. Each participant will be observed for 3 months.\n\nThe study will include 100 adults with type 1 or type 2 diabetes who use CGM and insulin therapy. By analyzing episodes of glucose levels below 70 mg\u002FdL during or after sexual activity, the study aims to determine whether sexual activity is associated with an increased risk of hypoglycemia. Findings may help to better understand patient concerns, reduce unnecessary fear, and develop future clinical recommendations for safe sexual activity in individuals treated with insulin.",[581,582,583],"Type 1 Diabetes (T1D)","Type 2 Diabetes (T2DM)","Hypoglycemia",[585,583,586,587,588,589,590,591,592],"Sexual Activity","Glucose Variability","Continuous Glucose Monitoring","CGM","Insulin Therapy","Type 1 Diabetes","Type 2 Diabetes","Diabetes Complications","2025-12-02",{"date":563,"type":43},{"date":596,"type":43},"2025-07-30",{"date":598,"type":23},"2028-07-10",{"name":49,"class":50},{"id":601,"slug":602,"hasResults":12,"nctId":603,"briefTitle":604,"officialTitle":604,"acronym":4,"eligibilityCriteria":605,"healthyVolunteers":12,"sex":18,"minAge":20,"maxAge":606,"enrollmentInfo":607,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":608,"conditions":609,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":612,"lastUpdatePostDateStruct":613,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":51},"100613738","the-effect-of-pharmacotherapy-with-glp-1-and-gipglp-1-analogs-on-changes-in-qualitative-and-quantitative-parameters-of-the-diet-as-well-as-metabolic-and-behavioral-parameters-in-patients-with-excess-body-weight-100613738","NCT07270497","The Effect of Pharmacotherapy With GLP-1 and GIP\u002FGLP-1 Analogs on Changes in Qualitative and Quantitative Parameters of the Diet as Well as Metabolic and Behavioral Parameters in Patients With Excess Body Weight","Inclusion Criteria:\n\n* Age 18-65 years,\n* Diagnosed obesity (BMI ≥ 30 kg\u002Fm²) or overweight (BMI ≥ 27 kg\u002Fm²) with comorbidities associated with excess body weight (including type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease),\n* Eligibility for treatment with GLP-1 or GIP\u002FGLP-1 analogues,\n* Not taking GLP-1 and GIP\u002FGLP-1 analogue medications for at least one year prior to study enrollment,\n* Ability to provide informed consent,\n* Informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Age under 18 or over 65 years,\n* Inability to qualify for treatment with GLP-1 and GIP\u002FGLP-1 analogues,\n* Pregnancy or breastfeeding,\n* Diagnosed eating disorders,\n* Active cancer or gastrointestinal conditions that may affect the absorption or tolerance of treatment (e.g., inflammatory bowel disease, conditions after extensive gastrointestinal resections, conditions after bariatric surgery),\n* Inability to participate in regular follow-up visits,\n* Inability to provide informed consent,\n* Failure to provide informed consent to participate in the study.","65 Years",{"count":532,"type":23},"The aim of this study is to comprehensively assess the early and long-term effects of GLP-1 and GIP\u002FGLP-1 analogue medications on metabolic and behavioral parameters, with particular emphasis on qualitative and quantitative dietary changes in patients undergoing treatment for overweight and obesity. Participation in the study will involve four follow-up visits per year at the Clinic of Diabetology and Internal Medicine, Central Clinical Hospital, University Clinical Clinical Hospital, Medical University of Warsaw: before treatment initiation and after 3, 6, and 12 months. The analysis will focus not only on metabolic effects (weight loss, changes in body composition, and improved biochemical parameters), but also on nutritional and behavioral aspects, including diet, appetite regulation, risk of malnutrition and muscle loss, and the occurrence of adverse events. The study will allow for a multifaceted assessment of the impact of treatment with GLP-1 and GIP\u002FGLP-1 analogues on patients with excess body weight.",[610,611],"GLP-1","Nutrition","2025-11-25",{"date":614,"type":43},"2025-12-08",{"date":616,"type":43},"2025-08-15",{"date":618,"type":23},"2026-08-14",{"name":49,"class":50},{"id":621,"slug":622,"hasResults":12,"nctId":623,"briefTitle":624,"officialTitle":625,"acronym":4,"eligibilityCriteria":626,"healthyVolunteers":12,"sex":18,"minAge":20,"maxAge":4,"enrollmentInfo":627,"targetDuration":4,"studyType":24,"phases":629,"briefSummary":630,"conditions":631,"keywords":635,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":639,"lastUpdatePostDateStruct":640,"startDateStruct":642,"completionDateStruct":644,"leadSponsor":646,"locationsCount":51},"100611178","15-vs-45-minute-pringle-maneuver-in-liver-cancer-resection-randomized-noninferiority-trial-100611178","NCT07237204","15 vs 45 Minute Pringle Maneuver in Liver Cancer Resection: Randomized Noninferiority Trial","A Prospective, Randomized Noninferiority Trial Comparing 15- and 45-minute Pringle Maneuvers During Liver Resection for Oncologic Indications.","Inclusion Criteria:\n\n* Diagnosis of a primary or secondary malignant liver tumor.\n* Age \\> 18 years.\n* Patient deemed eligible for liver resection.\n* WHO performance status ≤ 2.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Liver cirrhosis.\n* Liver dysfunction classified as Child-Pugh class B or C.\n* Repeat hepatectomy.\n* Prior ablation or chemoembolization of hepatic lesions.\n* Prior portal vein branch embolization.\n* Planned or performed ALPPS procedure.\n* Concomitant resection of any organ other than the gallbladder during the same operation.",{"count":628,"type":23},600,[26],"The goal of this clinical trial is to evaluate the safety of two durations of the Pringle maneuver in adults undergoing elective liver resection for malignant tumors. The main questions it aims to answer are:\n\nIs the incidence of post-hepatectomy liver failure different between 15-minute and 45-minute Pringle maneuver durations?\n\n* Do the durations differ in operative time or intraoperative blood loss?\n* Researchers will compare patients randomized 1:1 to 15 minutes vs 45 minutes of Pringle clamping to see if outcomes are non-inferior between groups.\n\nParticipants will:\n\n* Undergo standard oncologic hepatectomy with the assigned Pringle duration.\n* Receive routine perioperative assessments, including laboratory tests and clinical evaluations.\n* Attend follow-up visits at approximately 6 months, 1 year, and 3 years after surgery.",[632,633,634],"Liver Cancer, Adult","Metastases to Liver","Liver Malignant Tumors",[636,637,638],"Pringle manouver","Liver malignancy","Liver resection","2025-11-14",{"date":641,"type":43},"2025-11-19",{"date":643,"type":23},"2025-12-01",{"date":645,"type":23},"2030-11-01",{"name":49,"class":50},{"id":648,"slug":649,"hasResults":12,"nctId":650,"briefTitle":651,"officialTitle":652,"acronym":653,"eligibilityCriteria":654,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":655,"enrollmentInfo":656,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":658,"conditions":659,"keywords":662,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":639,"lastUpdatePostDateStruct":665,"startDateStruct":667,"completionDateStruct":669,"leadSponsor":671,"locationsCount":4},"100610820","biomarkers-and-respiratory-omics-as-new-children-opportunities---study-of-clinical-outcomes-and-predictivity-evaluation-100610820","NCT07232550","Biomarkers and Respiratory Omics as New CHildren Opportunities - Study of Clinical Outcomes and Predictivity Evaluation","Biomarkers and Respiratory Omics as New CHildren Opportunities - Study of Clinical Outcomes and Predictivity Evaluation - a Multi-cohort, Multi-center Study","BRONCHOSCOPE","Inclusion Criteria:\n\n* Age at the beginning of the study 0-17 years old\n* Clinical indication and qualification by the attending physician for fiberoptic bronchoscopy under general anesthesia:\n\n  * Obstruction of the airways:\n  * Suspicion of foreign body aspiration\n  * Persistent stridor\n  * Abnormal result of functional tests of respiratory system - flattening of inspiratory or expiratory curve, presence of restriction (tested vital capacity \\\u003C5 percentile) or irreversible obstruction (persistence of Tiffneau index \\\u003C5 percentile despite administration of bronchodilators)\n  * Radiological findings located in the course of the larynx, trachea or bronchi\n  * Persistent atelectasis on subsequent radiological examinations\n  * Persistent cough \\>4 weeks\n  * Hemoptysis\n  * Suspected laryngomalacia or tracheobronchomalacia\n  * Suspected tracheoesophageal fistula\n  * Persistent dyspnea unresponsive to anti-asthmatic treatment used for min. 2 months, with no other identifiable causes\n  * Radiologically detected mediastinal abnormalities\n  * Suspected presence of a vascular ring\n  * Presence of excessive secretions that are impossible for the patient to expectorate\n  * Fine needle biopsy of cystic lesions\n* Obtained consent from patient\u002Flegal guardian for participation in the study\n\nExclusion Criteria:\n\n* Active acute respiratory infection up to 4 weeks before the procedure\n* Taking antibiotics or systemic glucocorticosteroids up to 4 weeks before the procedure\n* Patients with very severe comorbidities (congenital immunodeficiencies, genetic disorders, neurological or neuromuscular diseases, cancer, severe congenital heart defects, heart failure, liver failure, inflammatory bowel disease, celiac disease)\n* Patients with blood clotting disorders\n* Children with diagnosed respiratory diseases other than asthma and protracted bacterial bronchitis - including interstitial diseases, tuberculosis, inflammation of small and medium-sized blood vessels\n* Patients for whom \\>48 hours have passed between suspicion of foreign body aspiration and interventional bronchoscopy\n* Children with foreign body aspiration having a foreign body located in the trachea","17 Years",{"count":657,"type":23},160,"The goal of this observational study is to improve the identification of biomarkers that predict disease progression and to assess the effectiveness of current therapies in children with asthma and protracted bacterial bronchitis.\n\nThe main aim of the study is to evaluate the microbiome composition and diversity, cellular composition, and metabolomic profile. In addition, to assess their correlation on subsequent treatment and disease course in children with asthma, protracted bacterial bronchitis, and in those receiving inhaled glucocorticosteroids without a diagnosis of asthma.\n\nParticipants will undergo fiberoptic bronchoscopy. During bronchoscopy, the performing physician will collect Bronchoalveolar lavage fluid samples for metagenomic and metabolomic analysis, as well as mucosal biopsies for histopathological evaluation.",[660,661,65],"Asthma in Children","Protracted Bacterial Bronchitis",[663,664],"PBB","Asthma",{"date":666,"type":43},"2025-11-18",{"date":668,"type":23},"2025-11",{"date":670,"type":23},"2035-12",{"name":49,"class":50},{"id":673,"slug":674,"hasResults":12,"nctId":675,"briefTitle":676,"officialTitle":677,"acronym":4,"eligibilityCriteria":678,"healthyVolunteers":12,"sex":18,"minAge":679,"maxAge":655,"enrollmentInfo":680,"targetDuration":4,"studyType":24,"phases":682,"briefSummary":683,"conditions":684,"keywords":686,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":688,"lastUpdatePostDateStruct":689,"startDateStruct":691,"completionDateStruct":693,"leadSponsor":695,"locationsCount":51},"100605138","sustained-unresponsiveness-su-to-cashew-nut-protein-following-oral-allergen-specific-immunotherapy-100605138","NCT07158619","Sustained Unresponsiveness (SU) to Cashew Nut Protein Following Oral Allergen-Specific Immunotherapy","Evaluation of the Acquisition of Sustained Unresponsiveness to Cashew Nut Protein Following Oral Allergen-Specific Immunotherapy - Long-Term Follow-Up of Patients From the RCT \"Efficacy of Cashew Nut Protein Immunotherapy: A Protocol of a Single-Center Randomized Controlled Trial in the Pediatric Population\" (NCT06328504)","Inclusion Criteria:\n\n* Cashew nut allergy confirmed prior to the initiation of immunotherapy\n* Completion of the first phase of the study, including achievement of the maintenance dose (1200 mg of cashew nut protein) during immunotherapy\n* Provision of informed consent for participation in the study\n* Adequate cooperation from the patient and\u002For their legal guardians\n\nExclusion Criteria:\n\n* Severe asthma\n* Poorly controlled mild-to-moderate asthma, defined as:\n\n  * FEV1 \\\u003C 80% (below the 5th percentile),\n  * FEV1\u002FFVC ratio \\\u003C 75% (below the 5th percentile),\n  * Hospitalization due to asthma exacerbation within the past 12 months\n* Oral, sublingual, or subcutaneous immunotherapy for other allergens during the first year\u002Fseason of therapy\n* Eosinophilic gastrointestinal disorders\n* Severe, recurrent episodes of anaphylaxis within the last 6 months\n* Chronic illnesses requiring ongoing treatment, including:\n\n  * Cardiac conditions\n  * Epilepsy\n  * Metabolic disorders\n  * Diabetes mellitus\n* Use of the following medications:\n\n  * Daily oral corticosteroid therapy \\>1 month within the past 12 months\n  * At least two courses of oral corticosteroids (minimum duration of 7 days each) in the past 12 months\n  * One course of oral corticosteroids (minimum 7 days) within the past 3 months\n  * Biologic therapies\n  * Treatment with β-blockers, ACE inhibitors, or calcium channel blockers\n* Pregnancy\n* Lack of informed consent for participation\n* Lack of cooperation from the patient","4 Years",{"count":681,"type":23},39,[26],"This study is a long-term follow-up of participants from the randomized controlled trial (RCT) \"Efficacy of Cashew Nut Protein Immunotherapy: A Protocol of a Single-Center Randomized Controlled Trial in the Pediatric Population\", NCT06328504. At the end of the original RCT all participants will undergo an open Oral Food Challenge (OFC) to assess desensitization after 3 months on the maintenance dose of OIT. Patients who have completed the first part of the study will be invited to the current part of the project:\n\n* First arm (initial experimental group) - patients will continue oral immunotherapy (OIT) with cashew nut protein (1200mg) for the next 8 months (+\u002F- 3 weeks).\n* Second arm (initial control group - one year on a cashew nut elimination diet) - patients will begin OIT following the protocol used in the first part of the study (RCT). Upon completion of this initial phase, they will continue immunotherapy for an additional 8 months (+\u002F- 3 weeks).\n\nAfter an additional 8 months (+\u002F- 3 weeks) of OIT, all study participants will undergo a 4-week cessation of treatment, followed by an open Oral Food Challenge (OFC) to assess the development of sustained unresponsiveness (SU).",[685],"Food Allergy in Children",[687],"food allergy, oral immunoteraphy, cashew nut allergy,","2025-09-04",{"date":690,"type":43},"2025-09-08",{"date":692,"type":23},"2025-09",{"date":694,"type":23},"2029-05",{"name":49,"class":50},""]